CL2023002601A1 - Compuestos agonistas beta del receptor de la hormona tiroidea - Google Patents
Compuestos agonistas beta del receptor de la hormona tiroideaInfo
- Publication number
- CL2023002601A1 CL2023002601A1 CL2023002601A CL2023002601A CL2023002601A1 CL 2023002601 A1 CL2023002601 A1 CL 2023002601A1 CL 2023002601 A CL2023002601 A CL 2023002601A CL 2023002601 A CL2023002601 A CL 2023002601A CL 2023002601 A1 CL2023002601 A1 CL 2023002601A1
- Authority
- CL
- Chile
- Prior art keywords
- thyroid hormone
- agonist compounds
- hormone receptor
- receptor beta
- beta
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 229940123876 Thyroid hormone receptor beta agonist Drugs 0.000 title 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 abstract 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000005495 thyroid hormone Substances 0.000 abstract 1
- 229940036555 thyroid hormone Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proporcionan en la presente descripción compuestos, preferentemente compuestos agonistas del receptor beta de la hormona tiroidea (THR beta), composiciones de estos, y métodos de su preparación, y métodos para agonizar el THR beta y métodos para tratar trastornos mejorados por la activación del THR beta.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163156227P | 2021-03-03 | 2021-03-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023002601A1 true CL2023002601A1 (es) | 2024-03-22 |
Family
ID=83154837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023002601A CL2023002601A1 (es) | 2021-03-03 | 2023-09-01 | Compuestos agonistas beta del receptor de la hormona tiroidea |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240059682A1 (es) |
| EP (1) | EP4301357A1 (es) |
| JP (1) | JP2024510935A (es) |
| KR (1) | KR20230152095A (es) |
| CN (1) | CN117120051A (es) |
| AU (1) | AU2022228569A1 (es) |
| BR (1) | BR112023017612A2 (es) |
| CA (1) | CA3212130A1 (es) |
| CL (1) | CL2023002601A1 (es) |
| CO (1) | CO2023012684A2 (es) |
| IL (1) | IL305495A (es) |
| MX (1) | MX2023010324A (es) |
| PE (1) | PE20240097A1 (es) |
| WO (1) | WO2022187403A1 (es) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4197307A (en) * | 1977-04-12 | 1980-04-08 | Ciba-Geigy Corporation | 2-Alkylthio-, 2-alkylsulphinyl- and 2-alkylsulfonyl-6-phenylbenzimidazoles as anthelmintic agents |
| CN105477636B (zh) * | 2015-10-16 | 2019-09-17 | 厦门大学 | 使用阿维菌素及其衍生物治疗代谢疾病的方法 |
| TW202220968A (zh) * | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| WO2020041741A1 (en) * | 2018-08-24 | 2020-02-27 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| CA3110576A1 (en) * | 2018-09-18 | 2020-03-26 | Terns, Inc. | Compounds for treating certain leukemias |
| AU2019357618A1 (en) * | 2018-10-12 | 2021-04-29 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| CN111320609A (zh) * | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| WO2020227549A1 (en) * | 2019-05-08 | 2020-11-12 | Aligos Therapeutics, Inc. | MODULATORS OF THR-β AND METHODS OF USE THEREOF |
-
2022
- 2022-03-02 KR KR1020237032893A patent/KR20230152095A/ko unknown
- 2022-03-02 US US18/548,650 patent/US20240059682A1/en active Pending
- 2022-03-02 JP JP2023553065A patent/JP2024510935A/ja active Pending
- 2022-03-02 IL IL305495A patent/IL305495A/en unknown
- 2022-03-02 AU AU2022228569A patent/AU2022228569A1/en active Pending
- 2022-03-02 EP EP22764006.7A patent/EP4301357A1/en active Pending
- 2022-03-02 CA CA3212130A patent/CA3212130A1/en active Pending
- 2022-03-02 WO PCT/US2022/018575 patent/WO2022187403A1/en active Application Filing
- 2022-03-02 MX MX2023010324A patent/MX2023010324A/es unknown
- 2022-03-02 CN CN202280027156.1A patent/CN117120051A/zh active Pending
- 2022-03-02 PE PE2023002483A patent/PE20240097A1/es unknown
- 2022-03-02 BR BR112023017612A patent/BR112023017612A2/pt unknown
-
2023
- 2023-09-01 CL CL2023002601A patent/CL2023002601A1/es unknown
- 2023-09-26 CO CONC2023/0012684A patent/CO2023012684A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20240097A1 (es) | 2024-01-18 |
| KR20230152095A (ko) | 2023-11-02 |
| CN117120051A (zh) | 2023-11-24 |
| MX2023010324A (es) | 2023-11-09 |
| CA3212130A1 (en) | 2022-09-09 |
| AU2022228569A1 (en) | 2023-10-12 |
| BR112023017612A2 (pt) | 2023-12-05 |
| IL305495A (en) | 2023-10-01 |
| US20240059682A1 (en) | 2024-02-22 |
| WO2022187403A1 (en) | 2022-09-09 |
| CO2023012684A2 (es) | 2023-10-19 |
| JP2024510935A (ja) | 2024-03-12 |
| EP4301357A1 (en) | 2024-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP18094857A (es) | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo | |
| MX2020011562A (es) | Agonistas del receptor de la hormona tiroidea y usos de los mismos. | |
| BR112021013824A2 (pt) | Receptores de antígeno quiméricos gprc5d e células que expressam os mesmos | |
| CL2018003322A1 (es) | Inhibidores peptídicos del receptor de interleucina 23 y sus uso para tratar enfermedades inflamatorias. (divisional solicitud 201800128) | |
| PA8805801A1 (es) | Agonistas novedosos de los receptores de glucorticoides | |
| CO2020000056A2 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de la fibrosis | |
| CO2022006712A2 (es) | Inhibidores de las cinasas raf | |
| CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
| CL2019001963A1 (es) | Método para tratar o mejorar trastornos metabólicos mediante el uso de agonistas del receptor glp-1 conjugados con antagonistas del receptor del péptido inhibidor gástrico (gipr). | |
| UY37606A (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas | |
| CL2019003270A1 (es) | Carboxamidas de octa hidrofenantreno - bis y conjugados de proteína. | |
| BR112021019334A2 (pt) | Anticorpos de cadeia pesada que se ligam ao psma | |
| CL2021001075A1 (es) | Agonista del receptor de glucocorticoides e inmunoconjugados de este solicitud divisional de 202001452) | |
| ECSP17038999A (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
| CU20210099A7 (es) | Anticuerpos de receptor de péptido natriurético 1 | |
| CL2021003272A1 (es) | Composición farmacéutica parenteral del agonista dual glp1/2 | |
| CL2021001818A1 (es) | Métodos y composiciones para el tratamiento del cáncer | |
| MX2020004810A (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas. | |
| CL2008003802A1 (es) | Compuestos derivados de tioeteres c-21, agonistas del receptor de glucocorticoide; composicion farmaceutica; y uso para el tratamiento o profilaxis de una enfermedad o afeccion inmune, autoinmune o inflamatoria, tales como artritis reumatoide y esclerosis multiple. | |
| CL2023002601A1 (es) | Compuestos agonistas beta del receptor de la hormona tiroidea | |
| CL2023001492A1 (es) | Anticuerpos anti-ly6g6d y métodos de uso. | |
| CO2022014093A2 (es) | Compuestos para su uso en afecciones inflamatorias | |
| CL2021001944A1 (es) | Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias | |
| CL2021003497A1 (es) | Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1 |